drugset
drugset / Trial / NCT02651740

Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea

NCT02651740 ↗

Phase 2/3 Unknown 10 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy as well as safety of rifaximin combined fecal microbiota transplantation(Gut microbiota reconstruction) in the treatment of IBS-D.

Timeline

Start
2016-04
Primary completion
2023-07
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 400 mg —

Indications

irritable bowel syndrome